Physician profile
Oliver Benes
NPI 1972742963
$2,902.77
in general payments reported to CMS, 2019-2025
37 companies · $332 in 2025
The $332 reported for 2025 was more than what 79% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $253 · 2021: $161 · 2022: $418 · 2023: $532 · 2024: $310 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.26 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $156.91 | 2019-2020 | |
| Indivior INC. | $148.93 | 2023-2025 | Sublocade |
| Amgen INC. | $147.93 | 2019-2022 | |
| Alkermes, INC. | $145.69 | 2022-2024 | Vivitrol, Vivitrol |
| Supernus Pharmaceuticals, INC. | $117.91 | 2019-2024 | Qelbree |
| Axsome Therapeutics, INC. | $117.51 | 2023-2024 | Auvelity |
| Pfizer INC. | $108.22 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.87 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $102.67 | 2019-2020 | |
| Braeburn INC. | $99.60 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $99.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.24 | 2019-2020 | |
| Allergan, INC. | $72.17 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $64.75 | 2022 | |
| Vanda Pharmaceuticals INC. | $63.49 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $56.07 | 2021-2024 | Rexulti |
| Lilly USA, LLC | $55.18 | 2019-2020 | |
| Astellas Pharma US INC | $43.94 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $38.75 | 2019-2020 | |
| Uswm, LLC | $35.27 | 2022 | |
| Amarin Pharma, INC. | $28.26 | 2019-2022 | |
| Lundbeck LLC | $26.84 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $24.98 | 2019 | |
| Genentech USA, INC. | $22.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.67 | 2019 | |
| Aimmune Therapeutics, INC. | $16.95 | 2025 | Zenpep |
| Shire North American Group INC | $16.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.66 | 2019 | |
| Orexo US, INC. | $13.87 | 2022 | |
| Boston Scientific Corporation | $13.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.23 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.23 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.20 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.85 | 2025 | Voquezna |
| Hologic Sales and Service, LLC | $8.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Benes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.